Unmet needs in the dyslipidemia market are expected to provide manufacturers with new avenues for development, says a new report by GlobalData.
Titled ‘PharmaPoint: Dyslipidemia – Global Drug Forecast and Market Analysis to 2025’, the report projects the dyslipidemia market to cross $29bn by 2025.
Unmet needs mostly exist in the areas of the mixed dyslipidemia space and the statin intolerant patient pool, where adjunctive pipeline drugs and new biologics are failing to provide relief. These patients form a large part of the patient groups who are not likely to receive biologic-based therapies and are currently being treated with statins, ezetimibe, or fibrates.
Ezetimibe, however, is not being favoured by physicians as it is not an efficacious lipid-lowering therapy. New pipeline drugs are, therefore, being used to treat this group of patients. Some of these drugs include Esperion’s ETC-1002, Gemphire’s gemcabene, and other cholesteryl ester transfer protein (CETP) inhibitors.
Targeting subgroups of patients that addresses needs of the whole dyslipidemia population instead of a statins-based approach is expected to be a better development strategy for manufacturers, opines Elizabeth Hamson, PhD, healthcare analyst for GlobalData.
Esperion is already following this approach for ETC-1002 and plans to establish the drug as a standard treatment for statin-intolerant patients.
Gemcabene and the CETP inhibitors are also expected to benefit from this approach. Manufacturers who employ a strategic approach of focusing on patient subgroups are expected to strengthen their presence in the market, adds Hamson.